---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-029608"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:30:53.941187+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell reports FY2024 net loss $11.6M; cash only $0.4M; raises $1.64M via warrant inducement

## Summary
- Net loss of $11.6M ($2.31 per share) improved from $17.2M loss ($6.00 per share) in 2023.
- Cash and short-term deposits fell to $0.4M at year-end from $1.5M; company entered warrant inducement to raise ~$1.64M on April 1.
- R&D spending reduced to $4.7M from $10.7M; G&A also cut to $7.0M from $10.7M.
- Phase 3b trial of NurOwn for ALS proceeding with FDA SPA; partnership with Pluri for manufacturing.

## SEC filing metadata
- accession: 0001104659-25-029608
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465925029608/0001104659-25-029608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465925029608/tm2510890d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-029608
- JSON: https://secwatch.observer/filing/0001104659-25-029608.json
- Plain text: https://secwatch.observer/filing/0001104659-25-029608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.